A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
about
Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's diseaseMonoamine oxidase B inhibitors for early Parkinson's diseaseThe role of oxidative stress in Parkinson's diseaseMAO-inhibitors in Parkinson's DiseaseAvailable and emerging treatments for Parkinson's disease: a reviewRasagiline - a novel MAO B inhibitor in Parkinson's disease therapyLocomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathwayNeuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesInhibitors of MAO-A and MAO-B in Psychiatry and NeurologyClinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson diseaseReview of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.New small molecules for the treatment of Parkinson's disease.Treatment disparities in Parkinson's disease.Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.Review: management of Parkinson's disease.Validation of an instrument to measure older adults' expectations regarding movement (ERM).Improving symptom control in early Parkinson's diseaseRevisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine AgonistRasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease.Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy.Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in ratsOxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectivesALS lessons learned from other neurological diseases. Parkinson's disease.Evidence from clinical trials: can we do better?Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings.New therapeutic approaches to Parkinson's disease including neural transplants.Rasagiline in the pharmacotherapy of Parkinson's disease--a review.Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.Catecholamines and Neurodegeneration in Parkinson's Disease-From Diagnostic Marker to Aggregations of α-Synuclein.A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.Drug Insight: new drugs in development for Parkinson's disease.Experimental designs for small randomised clinical trials: an algorithm for choice.Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies.Autosomal dominant Parkinson's disease and the route to new therapies.Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.Pharmacotherapy for Parkinson's disease.Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
P2860
Q24240186-67B2F1E7-749D-4E61-B930-150792206EF4Q24246514-13C4690E-1FDD-4AF5-BE96-AA79DA896D5AQ24307946-6119B50D-7D29-4CF8-BEFB-2E0911A1C302Q24629770-BF93631B-868D-4B07-B532-3613C6C4677BQ24633444-06004D47-108F-476B-A0D4-BBF30EF454D0Q24654614-495FEA0F-4108-41BA-ACB3-21522F90B296Q24671046-E69CA314-71FB-40CB-AA44-1A10424EDD03Q26747508-4C6FDA31-1D87-40AB-8531-096A7FE69E33Q28069609-96A5FE54-37C4-4AE7-BF87-19B3080253EEQ28262497-AF930CD2-1A1A-4F71-AA59-4104BB34CF69Q33260250-55344D33-7617-41AD-9981-55F5C4325B08Q33636631-605E4350-4853-4F77-B005-D5AD8A0830C1Q33796430-40A3095C-4186-46E0-B892-A2FA3DF76AB6Q34027880-706C3F2C-52DA-461C-A51B-C4BFBBE80F0CQ34332812-43A70A0B-9F4A-48A8-BB21-29B65CF761D4Q34399483-99A4900B-6D23-4C11-9F05-4E95CEB46921Q34409267-CFEA816E-116D-45D6-B1BE-AD3E11C3084CQ34504316-99636881-A1BF-4390-BD9D-BBD34E2934CDQ34651186-ABD791C8-F0FA-448B-AFFD-737ABD26FC09Q34725080-9C7936B4-63DA-4E67-9FFE-464D1D92D44BQ35047710-C1935B76-D241-4785-9CEE-A6E912986D8DQ35545032-0127F6B2-B6D7-4BA9-B364-7870BDF19B45Q35608958-C681666A-A5E6-4CBD-900C-833112ABBE2EQ35932111-E78F606C-CCDD-47C1-B442-E3649946DC72Q36045358-9CB14A37-813C-4C06-ADEF-4535F3ED46A0Q36106907-8466BADD-512A-4A48-8C7C-831071225D74Q36225073-A36F1E28-05A0-4505-82A1-7C0B773E21A2Q36273444-832F5627-A1E0-4DF0-BAC7-8950DD05774BQ36307876-EA9F8D51-FD56-4B33-AAB0-F004264CFC9AQ36335146-673E3C7E-0092-40D2-BF45-FBDDABA95E5FQ36495782-58AC39E4-8ACC-401A-9316-659C554B4D0FQ36499640-C6E897D6-2A39-4082-ADB3-1E0624D152D5Q36573882-840C4A4D-06E0-4964-AC77-75E5833A4C04Q36631654-90F3AF99-8402-4FFD-9076-EF8D7B901726Q36793954-43E02DE3-D2C9-4227-903D-CA9BE252B38DQ36806669-CED10026-92F2-4680-BDAB-1537486894D5Q36847250-5497D839-A8DA-4198-A69E-A17C37BFEFC2Q37005143-4D96B87E-BAA4-4DA3-A95B-F72D1D5F376CQ37016031-33315605-3490-4E5D-ABE1-F9090092AE02Q37016034-4ECC937C-7A2E-4C7D-B647-636DEABF0C17
P2860
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
@en
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
@nl
type
label
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
@en
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
@nl
prefLabel
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
@en
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
@nl
P1433
P1476
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
@en
P2093
Parkinson Study Group
P304
P356
10.1001/ARCHNEUR.61.4.561
P577
2004-04-01T00:00:00Z